Related Experiment Videos

Kasabach-Merritt syndrome: a case review

D M Szlachetka1

  • 1Department of Pediatrics, Tufts University School of Medicine, USA.

Neonatal Network : NN
|April 4, 1998
PubMed

Insights

Kasabach-Merritt syndrome (KMS) is a rare, life-threatening condition associated with hemangiomas, causing severe coagulopathy. Early diagnosis and treatment are crucial to reduce the high mortality rate linked to bleeding complications.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Vascular Biology

Background:

  • Hemangiomas are common benign vascular tumors in newborns, with most regressing spontaneously.
  • A small percentage of hemangiomas are associated with life-threatening complications, including coagulopathy.

Observation:

  • Kasabach-Merritt syndrome (KMS) is a severe complication characterized by hemangioma, disseminated intravascular coagulopathy, microangiopathic anemia, and thrombocytopenia.
  • Morbidity and mortality in KMS are significantly influenced by hemangioma size and location.
  • Untreated KMS carries a substantial mortality rate, primarily due to bleeding from consumptive coagulopathy.

Findings:

  • This case study reviews the pathophysiology, clinical presentation, diagnostic approaches, and treatment strategies for KMS.
  • The literature reports approximately 205 cases of KMS as of 1997.
  • Bleeding secondary to consumptive coagulopathy is the leading cause of death in KMS patients.

Implications:

  • Understanding KMS pathophysiology is vital for timely diagnosis and intervention.
  • Effective management requires a multidisciplinary approach addressing both the hemangioma and coagulopathy.
  • Further research is needed to improve outcomes and reduce the mortality associated with KMS.

Related Concept Videos